The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

The FDA granted fast track designation for rezpegaldesleukin for treating adults and children aged 12 years and older, ...

Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a ...

AbbVie on Wednesday said the Phase 3 study evaluating the safety and efficacy of Rinvoq in adults and adolescents with severe alopecia areata met its primary endpoint of 80% or more scalp hair ...

The FDA has granted a “Fast Track” designation to rezpegaldesleukin (REZPEG) as a treatment for severe-to-very severe ...

Those who get their hair back after an episode of alopecia probably didn’t have moderate to severe hair loss. Learn about ...

Rezpegaldesleukin targets the interleukin-2 receptor complex in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells.

Alopecia areata (AA) has a severe psychosocial impact, which is linked to illness perceptions and stigma more strongly than disease severity.

AbbVie released positive topline data from its phase 3 UP-AA trial demonstrating safety and efficacy for upadacitinib for ...

Nektar Therapeutics ( NASDAQ: NKTR) has announced that the FDA has awarded Fast Track designation to its experimental drug rezpegaldesleukin, a treatment for severe-to-very severe alopecia areata.

As Women with Alopecia Awareness Month comes to a close, WRBL spoke to a local woman impacted by the autoimmune condition.

A bbVie has reported encouraging topline outcomes from the first of two replicate trials of the Phase III UP-AA programme, ...